Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant in asthma patients with sputum eosinophilia
2018-004381-33Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Fevipiprant with Placebo (2 arms). Primary endpoint: Sputum eosinophil percentage change. Started Jun 2019; status: terminated.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on 2018-004381-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004381-33.